Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Infinity Pharmaceuticals Inc INFIQ

Healthcare Biotechnology
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K... see more

Recent & Breaking News (GREY:INFIQ)

Infinity Announces the Date of Its First Quarter 2014 Financial Results Conference Call and Webcast

Business Wire April 24, 2014

King: How the Oncology Drug Development Machine Builds Biotech Wealth

Equities.com March 17, 2014

Infinity Appoints Two Experienced Life Science Leaders to Its Board of Directors

Business Wire March 10, 2014

Infinity to Present at the Upcoming Bernstein Emerging Biotech Conference

Business Wire March 3, 2014

Infinity Provides Company Update and Reports Full-Year 2013 Financial Results

Business Wire February 25, 2014

Infinity to Participate in 3 Upcoming Conferences

Business Wire February 19, 2014

Infinity Announces the Date of Its Full-Year 2013 Financial Results Conference Call and Webcast

Business Wire February 11, 2014

Infinity Announces Promotion of David A. Roth to Chief Medical Officer

Business Wire February 4, 2014

Infinity Reports Phase 1 Data of IPI-145 at Sixth Annual T-Cell Lymphoma Forum

Business Wire January 23, 2014

Infinity Provides Key 2014 Goals and Financial Guidance

Business Wire January 13, 2014

Infinity to Present at J.P. Morgan Annual Healthcare Conference

Business Wire January 6, 2014

Infinity Reports Updated Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 in Chronic Lymphocytic Leukemia and T-Cell Lymphoma at ASH Annual Meeting

Business Wire December 8, 2013

Infinity Reports Updated Phase 1 Data of IPI-145 in Indolent Non-Hodgkin Lymphoma at ASH Annual Meeting

Business Wire December 7, 2013

Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B-Cell Lymphoma and T-Cell Acute Lymphoblastic Leukemia Suggesting Broad Potential of IPI-145 in Blood Cancers

Business Wire December 7, 2013

Infinity to Present at the Oppenheimer 24th Annual Healthcare Conference

Business Wire December 6, 2013

Infinity Announces New Date and Time for Credit Suisse 2013 Healthcare Conference Presentation and Webcast

Business Wire November 11, 2013

Infinity Reports Third Quarter 2013 Financial Results and Provides Company Update

Business Wire November 7, 2013

Infinity Announces Clinical and Preclincial Data to Be Presented at ASH 2013 Annual Meeting

Business Wire November 7, 2013

Infinity Announces the Date of its Third Quarter 2013 Financial Results Conference Call and Webcast

Business Wire October 24, 2013

Infinity Reports Topline Data from Phase 2 Study of Retaspimycin Hydrochloride, Its Hsp90 Inhibitor, in Patients with Non-Small Cell Lung Cancer

Business Wire September 25, 2013